person · Reporting owner
Parschauer Karah Herdman
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617 | Director | April 21, 2022 | October 03, 2022 |
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 18, 2021 | June 22, 2021 |
| Evolus, Inc.EOLS · Entity 5341 | Director | February 17, 2026 | February 20, 2026 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | EVP and Chief Legal Officer | August 03, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anebulo Pharmaceuticals, Inc.
Report date April 21, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2027-02-28 | Direct | 30,425 |
Reported balance
After 2022-04-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-04-21 · Grant · Acquired 30,425 · Balance 30,425 F1: 25% of the option vests on March 1, 2023. Thereafter, 1/48 of the option vests on a monthly basis over 36 months until the option becomes fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the option vests on March 1, 2023. Thereafter, 1/48 of the option vests on a monthly basis over 36 months until the option becomes fully vested.
Arcturus Therapeutics Holdings Inc.
Report date June 18, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.09 · Expires 2031-06-18 | Direct | 15,000 |
Reported balance
After 2021-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-18 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors.
Evolus, Inc.
Report date February 17, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,742 |
Reported balance
After 2026-02-17 transaction · row 1
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 45,559 · Balance 77,742 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Ultragenyx Pharmaceutical Inc.
Report date August 03, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,562 |
Reported balance
After 2026-08-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-03 · Sale · Disposed 1,900 · Balance 92,562 F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 4, 2026 19:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,900 | $24.92 | $47,348.00 |
DisclosureSEC source: 0001193125-26-332547 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,562 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 15, 2026 Filed Jun 15, 2026 22:46 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,899 | $24.62 | $46,753.38 |
DisclosureSEC source: 0001677455-26-000002 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,462 F1 · balance_after: Includes 646 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026 F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 28, 2026 Filed May 29, 2026 23:09 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001193125-26-249114 · ownership.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 49,960 | $0.00 Strike: $24.52 | $0.00 |
DisclosureSEC source: 0001193125-26-164281 · ownership.xml · derivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,960 Underlying: Common Stock · 49,960 shares Expires 2036-04-16 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:15 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 28,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164281 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,715 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 10, 2026 Filed Mar 10, 2026 20:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,508 | $22.67 | $79,526.36 |
DisclosureSEC source: 0001193125-26-100309 · ownership.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,820 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 20:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,018 | $21.40 | $128,785.20 |
DisclosureSEC source: 0001193125-26-100309 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,328 Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 23:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 8,135 | $22.80 | $185,478.00 |
DisclosureSEC source: 0001193125-26-089111 · ownership.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,346 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range F4 · balance_after: Includes 73 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2025 F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 11,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089111 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,408 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 01:57 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 45,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-26-000027 · wk-form4_1771552664.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,742 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 17, 2026, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| September 12, 2025 Filed Sep 12, 2025 20:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,450 | $31.17 | $76,366.50 |
DisclosureSEC source: 0001677455-25-000005 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,271 F1 · balance_after: Includes 434 shares acquired under the Company's A&R 2014 Employee Stock Purchase Plan on April 30, 2025. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 29, 2025 Filed May 30, 2025 22:48 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 107,400 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000950170-25-079941 · ownership.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2035-05-28 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 21:59 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 12,888 | $12.99 | $167,465.38 |
DisclosureSEC source: 0001570562-25-000046 · wk-form4_1741989579.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,183 F1 · price: The shares were sold in multiple trades at prices ranging from $12.98 to $13.025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:53 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 11,146 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001570562-25-000035 · wk-form4_1741733588.xml · derivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,146 Underlying: Common Stock · 11,146 shares Expires 2035-03-07 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of March 7, 2025, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:53 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 7,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-25-000035 · wk-form4_1741733588.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,071 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of March 7, 2025, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:18 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 12,846 | $42.10 | $540,816.60 |
DisclosureSEC source: 0000950170-25-032798 · ownership.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,287 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2025 Filed Mar 3, 2025 18:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 26,074 | $0.00 Strike: $42.92 | $0.00 |
DisclosureSEC source: 0000950170-25-030639 · ownership.xml · derivative · entry 4 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,074 Underlying: Common Stock · 26,074 shares Expires 2035-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2025 Filed Mar 3, 2025 18:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 14,494 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-030639 · ownership.xml · nonDerivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,690 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 205 shares acquired on October 31, 2024 under the Company's Amended and Restated Employee Stock Purchase Plan Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:18 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 18,443 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032798 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,133 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 18:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 760 | $42.75 | $32,490.00 |
DisclosureSEC source: 0000950170-25-030639 · ownership.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,991 Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 18:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,230 | $42.93 | $95,733.90 |
DisclosureSEC source: 0000950170-25-030639 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,751 Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 00:39 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 34,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000950170-24-116061 · ownership.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2034-10-17 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 31, 2025, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 23:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 9,806 | $45.00 | $441,270.00 |
DisclosureSEC source: 0000950170-24-072621 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,981 F1 · balance_after: Includes 447 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2024. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 31,400 | $0.00 Strike: $53.69 | $0.00 |
DisclosureSEC source: 0000950170-24-026666 · ownership.xml · derivative · entry 4 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Stock · 31,400 shares Expires 2034-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,756 | $53.76 | $201,922.56 |
DisclosureSEC source: 0000950170-24-026666 · ownership.xml · nonDerivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,340 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes 357 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on October 31, 2023. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 957 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026666 · ownership.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,739 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 17,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026666 · ownership.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,782 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:37 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 9,377 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001570562-24-000021 · wk-form4_1707521822.xml · derivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,377 Underlying: Common Stock · 9,377 shares Expires 2034-02-07 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of February 7, 2024, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 23:37 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 6,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-24-000021 · wk-form4_1707521822.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,707 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of February 7, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| January 30, 2024 Filed Feb 2, 2024 21:57 UTC | Evolus, Inc. EOLS · Entity 5341 | SaleCommon Stock | 11,931 | $13.14 | $156,732.77 |
DisclosureSEC source: 0001570562-24-000005 · wk-form4_1706911039.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,243 F1 · price: The shares were sold in multiple trades at prices ranging from $13.025 to $13.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 00:24 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 29,532 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036512 · doc4.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,532 Underlying: Common Stock · 29,532 shares Expires 2033-06-08 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| May 04, 2023 Filed May 5, 2023 18:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,378 | $45.00 | $197,010.00 |
DisclosureSEC source: 0001209191-23-027601 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,982 F1 · shares: The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F2 · balance_after: Includes 221 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 39,400 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-23-016047 · doc4.xml · derivative · entry 4 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,400 Underlying: Common Stock · 39,400 shares Expires 2033-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,161 | $45.25 | $143,035.25 |
DisclosureSEC source: 0001209191-23-016047 · doc4.xml · nonDerivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,139 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes 199 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2022. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016047 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,101 F2 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016047 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,101 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 01:41 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 11,789 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0001570562-23-000023 · wf-form4_167521568896760.xml · derivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,789 Underlying: Common Stock · 11,789 shares Expires 2033-01-27 F2 · derivative.exercise_date: The shares subject to the option will vest over a period of twelve months, with 1/12th of the shares subject to the option vesting monthly on the anniversary of January 27, 2023, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 01:41 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 8,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-23-000023 · wf-form4_167521568896760.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,174 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 27, 2023, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 23:25 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 20,000 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001209191-22-049362 · doc4.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-09-07 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| April 21, 2022 Filed Oct 3, 2022 23:56 UTC | Anebulo Pharmaceuticals, Inc. ANEB · Entity 9617 | GrantStock Option (right to buy) · Derivative | 30,425 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051983 · doc4.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,425 Underlying: Common Stock · 30,425 shares Expires 2027-02-28 F1 · derivative.exercise_date: 25% of the option vests on March 1, 2023. Thereafter, 1/48 of the option vests on a monthly basis over 36 months until the option becomes fully vested. Read SEC document |
| March 07, 2022 Filed Mar 8, 2022 17:25 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 5,140 | $62.95 | $323,563.00 |
DisclosureSEC source: 0001209191-22-016931 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,438 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.89 to $63.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 24,900 | $0.00 Strike: $67.37 | $0.00 |
DisclosureSEC source: 0001209191-22-015811 · doc4.xml · derivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2032-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015811 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,578 F3 · balance_after: Includes 106 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 29, 2021. F4 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,886 | $66.62 | $192,265.32 |
DisclosureSEC source: 0001209191-22-015811 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,472 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.62 to $66.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:01 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantStock Option (Right to Buy) · Derivative | 22,727 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001570562-22-000050 · wf-form4_164324889718833.xml · derivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,727 Underlying: Common Stock · 22,727 shares Expires 2032-01-24 F2 · derivative.exercise_date: The shares subject to the option will vest as to 1/12 of the underlying shares monthly from the vesting commencement date of January 24, 2022, provided the reporting person remains in continuous service on each vesting date, subject to accelerated vesting in certain events, including certain terminations of the reporting person or upon certain changes of control of the issuer. Read SEC document |
| January 24, 2022 Filed Jan 27, 2022 02:01 UTC | Evolus, Inc. EOLS · Entity 5341 | GrantCommon Stock | 15,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001570562-22-000050 · wf-form4_164324889718833.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,881 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of January 24, 2022, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 22:58 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to Buy) · Derivative | 19,495 | $0.00 Strike: $20.99 | $0.00 |
DisclosureSEC source: 0001209191-21-071136 · doc4.xml · derivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,495 Underlying: Common Stock · 19,495 shares Expires 2031-12-22 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest and become exercisable on January 22, 2022 and 1/36th of the shares subject to the option shall vest monthly thereafter provided that the Reporting Person remains a service provider to the Issuer on each vest date. Read SEC document |
| October 14, 2021 Filed Oct 18, 2021 22:46 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 310 | $81.14 | $25,153.40 |
DisclosureSEC source: 0001209191-21-060752 · doc4.xml · nonDerivative · entry 1 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,358 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 22:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,336 | $0.00 Strike: $54.50 | $0.00 |
DisclosureSEC source: 0001209191-21-055362 · doc4.xml · derivative · entry 3 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,664 Underlying: Common Stock · 7,336 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on June 20, 2017 (the first anniversary of the grant date of the option or the "Option Anniversary Date") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option fully vested on the fourth anniversary of the grant date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 22:22 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 7,336 | $100.65 | $738,368.40 |
DisclosureSEC source: 0001209191-21-055362 · doc4.xml · nonDerivative · entry 2 Parschauer Karah Herdman · CIK 0001677455 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,668 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.